Senseera, a Jerusalem, Israel-based liquid biopsy company, raised $7.1M in Seed funding.
The round was led by Lightspeed Venture Partners, with participation from I-Next Capital and the Lowy Medical Research Institute.
The company intends to use the funds to advance its GEM BIOMARKERS™ liquid biopsy platform, empowered by cfChIP-seq technology.
Led by CEO Dr. Ronen Sadeh, Senseera provides a platform, GEM BIOMARKERS™, that helps drug development in cancer and immune disorders. By offering simultaneous solid tissue and immune cell states monitoring, the platform also provides insights into tissue/tumor immune cross-talk, enabling researchers and clinicians to better understand the underlying mechanisms and support personalized treatments.
FinSMEs
07/01/2025